Artemis Investment Management LLP Buys Shares of 124,899 Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Artemis Investment Management bought a new stake of 124,899 shares of Amneal Pharmaceuticals (AMRX) in Q4, valued at about $1.57 million.
• Amneal beat Q4 estimates with earnings of $0.26 per share (vs. $0.15 expected) and revenue of $723M, and set FY2026 guidance of 0.95–1.05 EPS (Q1 guidance 0.27), with analysts projecting roughly 0.92 EPS for the year.
• Several institutions materially adjusted positions (e.g., Assenagon up 75% to 3.76M shares; Rubric holds 11.71M), institutional ownership is ~31.82%, and Wall Street ratings average a “Moderate Buy” with a $15 consensus target (UBS at $19).

Artemis Investment Management LLP bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 124,899 shares of the company's stock, valued at approximately $1,574,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMRX. Assenagon Asset Management S.A. raised its position in Amneal Pharmaceuticals by 75.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company's stock valued at $47,398,000 after purchasing an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter valued at $13,833,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Amneal Pharmaceuticals by 1,440.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company's stock valued at $11,790,000 after purchasing an additional 1,062,045 shares in the last quarter. Rubric Capital Management LP increased its stake in shares of Amneal Pharmaceuticals by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock valued at $94,737,000 after purchasing an additional 974,355 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Amneal Pharmaceuticals by 2,866.0% during the 4th quarter. SG Americas Securities LLC now owns 784,803 shares of the company's stock worth $9,889,000 after buying an additional 758,343 shares in the last quarter. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Stock Down 0.3%

Shares of AMRX stock opened at $12.83 on Friday. The company has a market cap of $4.04 billion, a price-to-earnings ratio of 33.76 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.02 and a 52 week high of $15.42. The firm has a 50 day moving average of $12.87 and a 200-day moving average of $12.63.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Wednesday, April 22nd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.11. The company had revenue of $723.00 million for the quarter, compared to the consensus estimate of $709.79 million. Amneal Pharmaceuticals had a net margin of 4.53% and a negative return on equity of 276.67%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.950-1.050 EPS and its Q1 2026 guidance at 0.270-0.270 EPS. Analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Zacks Research downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 6th. Truist Financial lifted their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Finally, UBS Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a "buy" rating and a $19.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.